Member Info for CityTTrader

That's a brilliant interview. Confirms so much and no cash requirement until APR-JUN next year. Plus so much about to happen here.

There has to be a reason for the ommission. Either its delayed but surely a vote should be held just to test how shareholders feel about it? Or they have a buyer(s) and things are moving very quickly.

I see it more as a second head and shoulders formation though maybe a bit lopsided. Very bullish though.

My suspicion over the last couple of days has been that a large buyer has given the MMs a price and they are trying to fill the order below that price in order to make more money. Today though it didn't work because too many buyers appeared and they couldn't hold it down first thing. Its been a while since a holdings RNS but one might come soon and it could be very interesting as to who it is.

Even 50k is still NT.

Its still not eay to buy. I just tried 100k but not a hope. Something cooking here.

SOmething about to happenhe graph is pointing higher.

Some (buyers) will say buy and others (Shorters) will say don't buy. What you have to do is research and get a feel forr the company. If you like what you see then buy and hold. Meaning longer than a week. Personally I look at potential news flow and the market loves a company going places with lots of good news in the pipeline ecept it tend to sit back and wit for the news to be confirmed. Ihave the advantage there because I try to buy ahead of that news flow.
If you think you cannot hold the shares for the news then don't buy. Many here think good things are going to happen here but its going to take time. You need to detach and return in at least 6 months.
You could pile in now and grab the STEM shares then sell some of your TILS holding to free up cash for a new share. I suggest this is what many here will do.

Its definitey a time of 'all aboard' if yu want the free shares in STEM.

An RNS could land any minute and this price will be history.

It could be that Gilead are using TILS inhaler but for other treatments and so patenting the use of a treatment with TILS inhaler?

TILS should have released an RNS today but haven't6. Does this mean that Gilead are not linked to TILS?

Er... none at all. All have been notified by RNS and are already priced into the share price.

I decided to go all in yesterday even though I already have a good position here. The mention of NDA's helped me decide. I tried a few times to buy 100,000 shares but not a hope. I the final 15 minutes I tried 36 times to buy 10,000 but the MM's just would not play. Makes me think they had another buyer in the background.

Looks as though the name of the buyer has been leaked.

Its about to jump up.

I'm wondering who would be sniffing around TILS just now? Bristol Myers Squib were mentioned a short while ago but who else could be out there and how long does it normally take to run the slide rule over a Pharma?

Several weeks ago we had the RNS about that patent applied for and I said at the time that this would lead to it being 'Patent applied for' status which is as good as having the patent because nobody could copy it. It now looks as though big pharma stood up and took notice.
The future now could be that we:
a) Sell the product to the big Pharma bagging a nice profit.
b) Licence the inhaler to any big pharma and live of the income stream.
c) Spin it off as a seperate company just like STEM.

My thoughts are that we shall sell the technology and use the cash for a dividend and to fund our other products through to production.

Exciting times ahead.

We all think you're an idiot.

Foralumab
Foralumab is a fully-human monoclonal anti-CD3 antibody, in-licensed from Novimmune SA in December 2014. It is being developed for treatment of inflammatory and autoimmune diseases.
Point mutations in the constant portion (Fc) of the antibody to minimize adverse immune responses (Cytokine Release Syndrome or CRS) produced by other anti-CD3 antibody therapeutics.
Foralumab binds to the T cell receptor complex (TCR) modulating levels of regulatory and effector T cells and the inflammatory response.
We believe that oral and intranasal administration of Foralumab has the potential to reduce inflammation while minimizing the toxicity and related side effects associated with intravenous administration.
Foralumab can be a potential therapy for nonalcoholic steatohepatitis, or NASH, and Crohn’s disease as well as neurodegenerative diseases such as multiple sclerosis, or MS.